Natalizumab-Associated Progressive Multifocal Leukoencephalopathy After Natalizumab Extended Interval Dosing Therapy in Japan
Given the high prevalence of JC virus antibody positivity in Japan, additional risk factors may contribute to NTZ-PML susceptibility. Although EID of natalizumab is expected to reduce PML risk, its effectiveness may be limited, particularly in Japanese individuals with high JC virus antibody titers.
Authors
- Motohiro Yukitake
- Nobuo Sanjo (ORCID: https://orcid.org/0000-0002-1226-2425)
- Tsuyoshi Hamaguchi (ORCID: https://orcid.org/0000-0002-1126-3776)
- Jin Nakahara (ORCID: https://orcid.org/0000-0002-5858-0998)
- Kazuo Nakamichi (ORCID: https://orcid.org/0000-0001-7594-2607)
- Koichiro Mori (ORCID: https://orcid.org/0000-0002-9518-0408)
- Masafumi Harada (ORCID: https://orcid.org/0000-0003-0958-1094)
- Kazuya Takahashi (ORCID: https://orcid.org/0000-0001-7532-4817)
- Hiroaki Yokote (ORCID: https://orcid.org/0000-0001-8620-5063)
- Masahito Yamada (ORCID: https://orcid.org/0000-0003-2416-5662)
- Ryusuke Ae (ORCID: https://orcid.org/0000-0003-2660-530X)
- Masaki Takao (ORCID: https://orcid.org/0000-0002-5392-996X)
- Yoshiharu Miura
Institutions
- Jichi Medical University (JP)
- Bunkyo University (JP)
- Kanazawa Medical University (JP)
- Keio University (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- National Institute of Infectious Diseases (JP)
- National Center of Neurology and Psychiatry (JP)
- Keio University Hospital (JP)
- Kudanzaka Hospital (JP)
- National Hospital Organization (JP)
- Shirasagi Hospital (JP)
- Tokushima University (JP)
Publication Details
- Journal
- Neurology Neuroimmunology & Neuroinflammation
- Published
- 2025-08-28
- DOI
- https://doi.org/10.1212/nxi.0000000000200476
- Citations
- 1
- Primary Topic
- Polyomavirus and related diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.05